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Small-cell lung cancer is characterized by a high
incidence of deletions on chromosomes 3p, 4q, 5q, IOq,
13q and 17p
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Summary The genetic mechanisms that define the malignant behaviour of small-cell lung cancer (SCLC) are poorly understood. We
performed comparative genomic hybridization (CGH) on 22 autoptic SCLCs to screen the tumour genome for genomic imbalances. DNA loss
of chromosome 3p was a basic alteration that occurred in all tumours. Additionally, deletions were observed on chromosome 1Oq in 94% of
tumours and on chromosomes 4q, 5q, 13q and 17p in 86% of tumours. DNA loss was confirmed by loss of heterozygosity (LOH) analysis for
chromosomes 3p, 5q and 1Qq. Simultaneous mutations of these six most abundant genetic changes were found in 12 cases. One single
tumour carried at least five deletions. DNA under-representations were observed less frequently on chromosome 15q (55%) and
chromosome 16q (45%). The prevalent imbalances were clearly indicated by the superposition of the 22 tumours to a CGH superkaryogram.
In our view, the high incidence of chromosomal loss is an indication that SCLC is defined by a pattern of deletions and that the inactivation of
multiple growth-inhibitory pathways contributes in particular to the aggressive phenotype of that type of tumour.
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Small-cell lung cancer (SCLC) accounts for about 18% of all
primary lung carcinomas (Ries et al, 1991), and the incidence is
rising especially in women (El-Torky et al, 1990). The mean
survival after diagnosis ranges between 6 and 18 months (Fox and
Scadding, 1973; Johnson et al, 1978; Medical Research Council,
1979), and SCLC is thus one of the most malignant tumours in
man. It may present itself as an acute disease with respiratory
insufficiency owing to a tumour bulk in the central bronchi associ-
ated with post-obstructive pneumonitis. The interval between
symptoms and diagnosis is shorter than in other types of lung
cancer. As dissemination occurs early, SCLC is usually considered
a systemic disease. This has lead to a therapeutic regimen that
avoids any surgical treatment and is based solely on chemotherapy
and radiotherapy.
Cytogenetic studies indicated almost 14 years ago that a deletion
on chromosome 3p is a characteristic finding in SCLC (Whang-
Peng et al, 1982). Although this was confirmed by molecular
genetic and molecular cytogenetic studies (Yokota et al, 1987; Mori
et al, 1989; Levin et al, 1994; Ried et al, 1994), 3p loss alone is not
sufficient to define SCLC, since it is also a frequent change in other
tumour entities, e.g. non-small-cell lung cancer (Tsuchiya et al,
1992; Sato et al 1994), head and neck squamous cell carcinoma
(Broszka et al, 1995; Speicher et al, 1995), bladder cancer
(Rodriguez et al, 1994) and cervix carcinomas (Yokota et al, 1989).
In addition, deletions on chromosomes 5q, 13q and 17p have previ-
ously been reported in SCLC (Yokota et al, 1987; Mori et al, 1989;
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Miura et al, 1992). Candidate tumour-suppressor genes (TSGs) that
are frequently inactivated are the retinoblastoma geneRb] at 13q14
(Kelley et al, 1995) andp53 at 17pl3 (Sameshima et al, 1992).
The amplification of myc oncogenes has been associated with
advanced tumour stages in SCLC (Takahashi et al, 1989) and the
overexpression ofthe c-myc oncoprotein correlated with poor prog-
nosis in head and neck squamous cell carcinomas (Field etal, 1989).
It is questionable, however, whether the evalution of single genetic
events is sufficient to define the malignant potential ofa tumour.
In the present study, we used comparative genomic hybridiza-
tion (CGH) to screen the genomes of 22 autoptic SCLCs for
genetic alterations. The analysis suggests that SCLC is character-
ized by a pattern ofalterations that include especially deletions on
chromosomes 3p, 4q, 5q, lOq, 13q and 17p. DNA loss of chromo-
some lOq is associated with tumour progression in gliomas
(Leenstra et al, 1994), menigeomas (Rempel et al, 1993) and
endometrial carcinomas (Peiffer et al, 1995). Accordingly, it might
contribute in particular to the malignant phenotype ofSCLC.
MATERIALS AND METHODS
Tumour specimens
The tumours were collected at autopsy perfomed between 8 and
36 h after the patients' death. The specimens were frozen in liquid
nitrogen and stored at -80°C until DNA was extracted. The clinico-
pathological data are shown in Table 1. Fourteen patients were
women and eight were men. The majority showed advanced tumour
stages. The primary tumour was investigated in 18 cases. In four
cases, the tumour specimens were derived from metastatic lesions,
i.e. in case 13 from a paratracheal lymph node metastasis, in cases
3 and 15 from a liver metastasis and in case 4 from a pleural
metastasis. Thirteen tumours that had been previously analysed
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Table 1 Clinicopathological data
Case Sex Age (Years) Stage
1 F 63 pT3 pN3 pMl
2 F 61 pT2 pNl pMO
3 M 71 pT3 pN2 pMl
4 F 59 pT4 pN3 pMl
5 F 46 pT4 pN3 pMl
6 M 83 pT3 pN3 pMl
7 F 57 pT3 pN2 pMl
8 M 50 pT4pNl pM1
9 M 75 pT4 pN3 pM1
10 F 80 pT2 pN2 pMl
11 F 66 pT3 pN3 pMl
12 F 67 pT2 pN0 pM0
13 F 56 pT4 pN3 pMl
14 F 58 pT4 pN3 pMl
15 M 55 pT3pNl pMl
16 M 80 pT4 pN3 pMl
17 F 57 pT3 pN3 pMl
18 M 78 pT3 pN3 pMl
19 F 33 pT3 pN2 pMl
20 F 79 pT4 pN3 pMl
21 F 70 pT4 pN3 pM0
22 M 75 pT2 pN3 pM0
(Ried et al, 1994) were rehybridized and assessed by a different
CGH analysis software (Wolfet al, 1995; Roth et al, 1996).
CGH preparation
Normal metaphase chromosomes were prepared from peripheral
blood lymphocytes by standard procedures. In general, no pepsin or
protease treatment was applied. The metaphase chromosomes were
denatured for90 s in 70% formamide/2 x saline sodiumcitrate (SSC)
at 77°C and dehydrated by an increasing ethanol series (70%, 90%,
100% EtOH). Each batch ofmetaphases was tested by hybridization
with differentially labelled normal DNA as described (Kallioniemi
et al, 1994). The tumour and normal DNA were labelled by nick
translation with biotin-dUTP and digoxigenin-dUTP (Bohringer
Mannheim, Mannheim, Germany) respectively. Tumour (l.g) and
I1,g ofnormal DNA plus 20 gg ofhuman Cotl DNA (Gibco BRL,
Life Technologies, Paisley, UK) was ethanol precipitated and the
DNA pellet was resuspended in 5 gl of formamide. After adding
10 jtl ofmaster mix (20% dextran sulphate/4 x SSC), the DNA was
denatured for 5 min at 77°C and prehybridized at 37°C for 1 h.
Finally, 12 gl was applied to the slide with the denatured and dehy-
drated metaphase chromosomes. Hybridization was done under a
18 x 18 mm coverslip that was sealed with rubber cement for
3 days at 37°C. The detection of the genomes was performed by
fluorescein-avidin (Vector Laboratories, Burlington, CA, USA) and
anti-digoxigenin-rhodamine (Bohringer Mannheim) without fluo-
rescence enhancement (Ried et al, 1992). DAPI was used for chro-
mosome counterstaining.
CGH image acquisition and digital image analysis
Three images per metaphase (DAPI, fluorescein isothiocyanate
(FITC), tetrarhodamine isothiocyanate (TRITC)) were acquired on
an Axiophot epifluorescence microscope (Zeiss, Oberkochen,
Germany) by using appropriate filter sets (DAPI: Zeiss filter set
02, i.e. excitation G365, beam splitter FT395, emission LP 420;
FITC: Zeiss filter set 20, i.e. excitation BP 450-490, beam splitter
FT 510, emission BP 546/12; TRITC: Chroma filter set HQ Cy3
plus excitation filter of Zeiss filter set 15, i.e. excitation BP
546/12, beam splitter FT 565, emission BP 570-650). The images
were stored under the TIFF format and analysed by a custom-
made CGH analysis program (Wolfet al, 1995; Roth et al, 1996).
It involves a karyotyping program (KARYOTYP, IBSB, Berlin)
that is based on the digital image analysis software AMBA,
which was developed in our laboratory (Roth et al, 1992). The
program is compatible with Windows 3.1 and Windows 95
(Microsoft, Redmont, WA, USA). Briefly, the digital image
analysis comprised the following steps:
1. definition ofthe image objects (chromosomes) by
segmentation ofthe inverted DAPI image;
2. loading ofthe FITC and TRITC image under the DAPI
segmentation mask;
3. correction ofthe optical shift ofthe FITC and TRITC image;
4. calculation ofthe RATIO (FITC/TRITC) image;
5. separation oftouching chromosomes;
6. karyotyping ofthe DAPI chromosomes (the FITC, TRITC
and RATIO chromosomes can be displayed during the
karyotyping process by means ofa 'compare' function); and
7. calculation ofthe mean ratio chromosomes (CGH sum-
karyogram) and the mean ratio profiles by averaging at least
five metaphases/karyograms.
In the CGH sum-karyogram (Figure IA), a particular mean ratio
chromosome is calculated from all chromosomes ofthe same class
that are present in the individual karyograms (Roth et al, 1996).
The CGH superkaryogram (Figure 3) is an extension of this
concept. A chromosome in CGH superkaryogram is calculated
by averaging the chromosomes of the same class of CGH sum-
karyograms of different tumours that belong to a specific tumour
entity (Manuscript in preparation).
LOH analysis
Paired samples of tumour and normal DNA were assessed for
allelic loss by microsatellite polymorphism or polymerase chain
reaction - restriction fragment lengthpolymorphism (PCR-RFLP)
analysis (Petersen et al, 1993). We investigated up to five different
markers on chromosome 3p that were located at 3pl3 (D3S659),
3pl3-14 (D3S30), 3p23 (D3S647) and 3p24 (THRB, EA2B),
three markers on chromosome Sq near the APC locus at 5q21-22
and two markers on chromosome lOq (DIOS169 and DIOS1213).
DIOS1213 is 18 cM centromic ofDIOS169, which was mapped to
the chromosomal band IOq26. The primer sequences and the PCR
conditions were used as published (Cottrell and Bodmer, 1992;
Ganly and Rabbitts, 1992a,b; Koorey et al, 1992; Miyoshi et al,
1992; Sakurai et al, 1992) or extracted from the Genome Database
via Internet (URL: http://gdbwww.gdb.org/). We used a non-
radioactive detection for the assessment ofmicrosatellite polymor-
phisms (Petersen et al, 1996).
RESULTS
The result ofthe CGH analysis ofcase 3 is shown in Figure 1. The
CGH sum-karyogram (Figure IA) and the ratio profile with the
95% confidence interval (Figure IB) were primarily used to define
the genetic changes in aparticulartumour. Ifthe mean ratio profile
was to the left of the monosomy threshold, it was considered a
deletion. If the mean ratio profile was to the right of the trisomy
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Figure 1 (A) CGH sum-karyogram of case 3. The chromosomes of eight metaphases/karyograms were included in the analysis. Deletions are depicted in red,
amplifications in green and equilibrium between the tumour and normal DNA in blue. Changes include deletions on chromosomes 3p11-14, 4q31-qter,
5q21-35, 10q21-qter, 13q11-14 and 17p11-pter. In addition, amplifications are present on chromosomes 2q32-34, 3q11-qter, 8p11 and on chromosome 19.
(B) Ratio profile of case 3 with the 95% confidence interval. The ratio profile represents the result as a one-dimensional curve. The three lines to the right of the
chromosome ideogram represent different fluorescence ratios, i.e. 0.75, 1 and 1.25. The central line corresponds to the normal state (fluorescence ratio 1:1).
The lines to the left and right represent the theoretical values of a monosomy or trisomy in 50% of the tumour cells of an otherwise diploid tumour. The number
of chromosomes analysed are indicated at each chromosome ideogram
threshold, it was judged as an over-representation. An over-
representation was defined as a high-copy amplification, if the
fluorescence ratio exceeded at least the value of 1.5. Every alter-
ation was re-evaluated by visual inspection ofall chromosomes of
the karyograms that were included in the CGH sum-karyogram. In
general, the 13 tumours that had been investigated previously by a
different CGH image analysis software (Ried et al, 1994) revealed
similarresults. In one case (no. 13), however, we observed aglobal
profile shift, i.e. the ratio profiles of all chromosomes were
displaced toward DNA loss by a fluorescence ratio value of about
0.5. Thus, those chromosomes that suggested no DNA loss in the
first analysis because the profiles were on the central line (fluores-
cence ratio 1:1) now indicated a DNA under-representation (fluo-
rescence ratio 0.5), whereas the other chromosomes, which
showed an over-representation, were normal in the present
analysis. The reason for the profile shift was owing to a misdefini-
tion of the so-called central line by the previously used program
(Thomas Ried, personal communication).
The summary of all alterations with reference to individual
cases is shown in Figure 2. In Figure 3, the aberrations ofall cases
were compressed to a CGH superkaryogram representing typical
changes ofthe tumour entity.
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Figure 2 Summary of all genetic alterations in the 22 SCLCs. Lines on the left of the chromosome ideogram represent a DNA loss; lines on the right represent
DNA gains. Solid bars indicate a high-copy amplification. The alterations of single cases can be identified by the number on top of each line or bar, which
corresponds to the case numbers of Table 1
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Figure 3 CGH superkaryogram of all 22 SCLCs. Typical changes are visible and include the DNA losses on chromosomes 3p, 4q, 5q, 1Oq, 13q and 17p and
DNA over-representations of 3q and 19
DNA losses
DNA under-representations were prevalent for chromosome 3p,
which was affected in all cases. In the majority ofcases, the whole
chromosomal arm was involved. Partial deletions occurred in
three cases and the entire chromosome 3 was lost twice. The CGH
and LOH analyses were consistent in each case.
Deletions on chromosome 10q were the second most frequent
finding, being observed in 20 tumours. A consensus region at
10q24-qter was affected in 19 cases (86%). The LOH analysis of
the two markers on chromosome 10q confirmed that this is a
commonly deleted region in SCLC. Sixteen out of 19 informative
cases (84%) showed allelic loss. Three examples are shown in
Figure 4. The CGH data were consistent with the LOH data except
for two cases. In case 12, the DNA loss by CGH could not be
confirmed by LOH analysis. A second tumour (case 8, Figure 4)
with no loss by CGH analysis clearly indicated a LOH for the
marker DIOS169 (see Discussion).
Losses on chromosomes 4q, 5q, 13q and 17p were seen in 86%
(19/22) of the cases. The CGH analysis indicated the existence of
two distinct regions ofdeletions for chromosome 5q, i.e. 5q21-22
and 5q31-qter. The LOH analysis supported the notion that in one
case (no. 1) the deletion was distal to the APC locus, since the
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tumour preserved heterozygosity for the markers at 5q2l-22.
Chromosome 15q was deleted in 12 cases (55%) and chromosome
16q in ten cases (45%).
DNA gains
DNA over-representations occurred most frequently on chromo-
some 3q (15/22, 68%) and 5p (12/22, 55%). These changes were
consistently accompanied by an over-representation of the corre-
sponding other chromosome arm, suggesting the formation of
isochromosomes 3q andSp respectively. High-copy amplifications
were observed at 5pll and 3q26.3-qter. DNA gains on chromo-
some 17q were observed in 11 cases (50%) and were accompanied
by 17p loss in 10 out of 11 cases.
Over-representations were also frequent for chromosomes 19
(13/22, 59%) and 20 (11/22, 50%). DNA gains occurred in
decreasing order of frequency at chromosomes 17q (11/22, 50%),
lq (8/22, 36%), 8q (7/22, 32%), 18 (7/22, 32%), llq (6/22, 27%),
lp (6/22, 27%) and 14q (6/22, 27%). High-copy amplifications
were mapped to chromosomes lp32-36, Iq21-24, lq41-qter,
2p23, 2q32-35, 7qll.2, 8pll, 8q21, 8q24.1, 9q21, 9q31,
llqll-14, Ilq25, 13q34, 15q24-qter, 17q21, 17q25, l9pl2,
19q13, 20p11, 21q22 and 22q1.
Numbers of changes
The total number of aberrations per tumour varied between 5 and
27 with a mean of 18.3. The deletions outnumbered the over-repre-
sentations in 19 cases. The under-representations per tumour
varied between 4 and 17 with a mean of 11.1, whereas the over-
representations were between 1 and 13 with a mean of7.1. In total,
we observed 245 DNA gains and 157 DNA losses in the 22
tumours analysed. Simultaneous loss of the most frequently
affected chromosomes, i.e. 3p, 4q, 5q, 10q, 13q and 17p, was
found in 12 cases.
DISCUSSION
Only a few years after its initial description (Kallioniemi et al,
1992), CGH has been established as a powerful screening method
in tumour genetics. Its main advantage is the detection of multiple
alterations in the form of a genetic pattem within a single experi-
ment. CGH has been used previously for the detection of aberra-
tion in SCLC (Levin et al, 1994; Ried et al, 1994). In our study, we
put particular emphasis on the characterization ofthe deletions.
Figure 4 Example of DNA loss on chromosome 1Oq assessed by LOH
analysis. Cases 2 and 8 were analysed for the marker DlOS1213 and case
5 for the marker Dl OS169. The tumour sample (T) showed only one band
compared with the paired normal sample (N) of the same patient as evidence
for allelic loss
Deletions
Deletions on chromosome 3p were observed in all tumours. In
the majority of them, the entire chromosomal arm was lost.
Partial deletions in three cases were confined to two distinct non-
overlapping regions at 3pll-14 and 3p21-pter. They co-localize
with regions having previously been implicated as loci of potential
tumour-suppressor genes (Hibi et al, 1992). The von Hippel-Lindau
(VHL) gene at 3p25-26 is only rarely mutated in lung cancer cell
lines (Sekido et al, 1994). Recently, the FHIT gene has been identi-
fied as a potential tumour-suppressor gene (Ohta et al, 1996). It is
located at 3pl4.2 and showed exonic losses in 80% of small-cell
lung carcinomas (Sozzi et al, 1996), which makes it a prime candi-
date for lung carcinogenesis.
DNA loss of chromosome 10q was the second most frequent
finding. This change has been observed previously (Ried et al,
1994; Levin et al, 1994), however at a lower incidence. The
discrepancy compared with the other CGH studies might be
explained by karyotyping errors. Chromosome 10 is difficult to
identify on the basis of the chromosome banding by DAPI fluores-
cence. In particular, it might be confused with chromosome 8,
which showed more frequent over-representations on the long arm
in the previous studies. In our experience, it is helpful to employ a
CGH analysis software that is based on a karyotyping program and
allows the visualization of the different fluorescence signals
during the karyotyping process. Patticularly, the ratio image of the
chromosomes representing the changes within a single metaphase
facilitates the identification of homologous chromosomes, if they
carry a characteristic change and, thus, reduces karyotyping errors.
We confirmed DNA loss on chromosome 10q by LOH analysis,
which resulted in a similar incidence of deletions for this chromo-
somal arm. The minimal region of deletion was at 10q24-qter.
Deletions on chromosome 10q have been described in gliomas
(von Deimling et al, 1992; Leenstra et al, 1994), malignant meni-
geomas (Rempel et al, 1993), endometrial carcinomas (Peiffer et
al, 1995) and melanoma (Isshiki et al, 1993). This change has been
associated with tumour progression, which corresponds well with
the fact that SCLC is generally an advanced and aggressive
tumour. Recently, the MXI1 gene has been identified as a candi-
date tumour-suppressor gene in prostate cancer (Eagle et al, 1995).
It is located at 10q24-25 and encodes a protein that negatively
regulates the myc oncogene (Schreiber-Agus et al, 1995). This is
intriguing, since amplification and overexpression of myc onco-
genes have been reported in small-cell lung cancer (Wong et al,
1986; Brennan et al, 1991) and are associated with advanced
tumour stages (Takahashi et al, 1989).
Candidate tumour-suppressor genes for the regions that are most
often deleted include the retinoblastoma gene RbJ at 13q14 and
p53 at 17pl3. In particular, DNA loss on chromosome 13q affected
the locus of the RbJ gene at 13q14 in all except one case. This
corresponds well with the fact that the Rbl protein is frequently
inactivated or lost in SCLC (Kelley et al, 1995). The incidence of
DNA loss on chromosome 17p by CGH correlated with the
frequency ofmutations at thep53 locus. Allelic loss and mutations
ofthep53 gene occurred in 96% and 85% of tumours respectively,
in a series of 27 patients with SCLC (Sameshima et al, 1992).
The role of MCC and APC, two tumour-suppressor genes that
map to 5q21-22, in lung carcinogenesis has not yet been fully
elucidated. Both genes have been implicated primarily in the
formation of tumours in the gastrointestinal tract. Although the
APC/MCC locus is frequently deleted in lung carcinomas, a
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centromeric region at 5q13-14 (Wieland and Bohm, 1994) and a
telomeric region at 5q33-35 (Hosoe et al, 1994) are additionally
affected, suggesting that there are different tumour-suppressor
genes on 5q associated with lung cancer.
A single paper reported 4q deletions in 6 of 16 (37.5%) SCLC
cell lines (Sekido et al, 1993). Allelic loss on chromosome 4q has
also been shown in hepatocellular carcinomas (Buetow et al, 1989;
Urano et al, 1991) and bladder cancer, indicating two distinct
regions (Polascik et al, 1995). We observed deletions in a centro-
meric region at 4qll-23 and a consensus telomeric region at
chromosomal band 4q32. To our knowledge, no tumour-suppressor
gene has yet been identified on this chromosome.
Copy number decreases occurred less frequently on chromo-
some 15q (55%) and chromosome 16q (45%). Deletions on
chromosome 15q were recently observed by LOH analysis in
multiple tumours, including carcinomas of the lung. They were
associated with progression to metastatic stage in breast carci-
nomas (Wick et al, 1996).
DNA over-representation
DNA amplification, being ageneral characteristic oftumour progres-
sion (Brison, 1993), is a frequent finding in SCLC. We observed
DNA gains in particular for chromosomes 3q and Sp. In each case,
they were accompanied by a DNA loss on the other chromosomal
arm. The DNA gain ofan entire chromosome arm may correlate to a
low-level overexpression of multiple genes that reside on this chro-
mosome arm. However, the fact that high-copy amplifications were
observed at Spl 1 and 3q26.3-qter probably indicates that the activa-
tion of specific proto-oncogenes contributes to a growth advantage
for cells that carry a 3q or 5p gain. DNA over-representation of3q or
amplification of the telomeric part of chromosome 3q have recently
been described in head and neck squamous cell carcinomas (Speicher
et al, 1995; Brzoska et al, 1995).
The single most frequent high-copy amplification was mapped
to chromosome 19q13, which has been previously described
(Ried et al, 1994). Thefos-B proto-oncogene is located at 19q13.3
and constitutes a candidate gene, since it is expressed in 60%
of non-small-cell lung carcinomas (Wodrich and Volm, 1993).
Additionally, we observed amplifications on the short arm ofchro-
mosome 19 twice. A proto-oncogene in this region is the rel gene
that was identified by the transfection of DNA from a human
melanoma cell line into NIH3T3 mouse fibroblasts. It was mapped
to l9cen-pl3.2 (Nimmo et al, 1991) and was overexpressed in a
small proportion of human gliomas (Watkins et al, 1994).
CGH superkaryograms in tumour classification
The sum-karyograms ofthe 22 SCLCs were compressed to a CGH
superkaryogram (Figure 3). In this representation, the prevalent
findings of the tumour class are still visible. This is promising,
since it seems feasible to characterize a tumour entity or subgroup
by its pattern of genetic changes, as revealed by CGH. The
computer-assisted comparison of the CGH pattern of a single
tumour with typical alterations of different tumour entities might
become a useful adjunct in tumour classification.
The correlation between the known genetic aberrations, e.g. Rb]
and p53, and the chromosomal abnormalities revealed by CGH is
striking. Thus, by careful examination of the CGH patterns, it is
possible to correlate certain changes with a tumour phenotype and
the biological behaviour, although the causative gene defect has
not yet been identified.
Multiple changes within one chromosome
We frequently observed DNA gains and losses on the same chro-
mosome, e.g. chromosomes 2q, 3 and 8p in Figure IA. Such a
pattern has recently been observed for chromosome 12 in gliomas
by molecular genetic methods (Reifenberger et al, 1995). It is
consistent with a proposed model for DNA amplification by chro-
mosome breakage (Windle et al, 1991), and CGH is an ideal tool
for the detection ofthis type ofchromosomal instability.
Amplifications might complicate the interpretation ofthe allelic
state, since the assessment of LOH is based on the comparison of
the band intensities of the two alleles. The increased intensity of
one band compared with the othermight actually correspond to the
amplification of one allele rather than an allelic loss. The correla-
tions between the LOH and CGH analysis in our study are in
agreement with those reported in the literature (Kallioniemi et al,
1994). Additional events that might lead to contradictory results
between CGH and LOH analysis are submicroscopical deletions
beyond the resolution ofCGH, mitotic recombination and chromo-
somal loss followed by reduplication. These mechanisms have
been discussed previously (Ried et al, 1994).
Multiple changes per tumour
The study showed that deletions in general were more prevalent
than amplifications. In particular, DNA under-representations of
the frequently deleted loci on chromosomes 3p, 10q, 5q, 4q, 13q
and 17p were each more prevalent than any of the observed over-
representations. These loci were simultaneously affected in 12
cases. In our view, this is an indication that SCLC is actually
defined by this pattern of deletions. The recent findings that the
number of deletions correlates with the clinical outcome of breast
cancer (Isola et al, 1995), renal carcinomas (Moch et al, 1996) and
head and neck squamous cell carcinoma (Li et al, 1994) support
the hypothesis that, in particular, the presence ofmultiple deletions
determines the poor prognosis for SCLC patients.
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